ArticleCancer biology & therapy2013

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Mhd Yaser Al-Marrawi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.